Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
762,7 USD | +1,13% | +3,85% | +30,83% |
Vakgebied
- endocrinologie (46,6%): producten voor de behandeling van osteoporose, diabetes en groeiproblemen;
- oncologie (20,3%);
- immunologische ziekten (11,8%);
- neurologie (6,7%): hoofdzakelijk geneesmiddelen voor de behandeling van depressie en schizofrenie;
- andere (14,6%).
De netto-omzet is geografisch als volgt verdeeld: de Verenigde Staten (59,4%), Europa (16,9%), Japan (8,3%), China (5,9%) en andere (9,5%).
Aantal werknemers: 43 000
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Human Pharmaceutical Products
100,0
%
| 28 541 | 100,0 % | 34 124 | 100,0 % | +19,56% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
63,9
%
| 18 190 | 63,7 % | 21 791 | 63,9 % | +19,80% |
Europe
18,1
%
| 4 299 | 15,1 % | 6 175 | 18,1 % | +43,62% |
Other Foreign Countries
8,6
%
| 2 852 | 10,0 % | 2 946 | 8,6 % | +3,30% |
Japan
4,9
%
| 1 747 | 6,1 % | 1 673 | 4,9 % | -4,28% |
China
4,5
%
| 1 453 | 5,1 % | 1 540 | 4,5 % | +5,98% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01-01-96 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 01-10-13 |
Ruth Gimeno
PSD | President | - | - |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | - | 17-05-21 |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16-10-23 |
Alonzo Weems
CMP | Compliance Officer | - | 01-01-97 |
Chief Tech/Sci/R&D Officer | 50 | 01-01-18 | |
Corporate Officer/Principal | - | 01-01-05 | |
Ilya Yuffa
PRN | Corporate Officer/Principal | 49 | - |
Ronald DeMattos
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 64 | 25-01-21 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 01-04-09 |
Jon Fyrwald
BRD | Director/Board Member | 64 | 01-01-05 |
Juan Luciano
BRD | Director/Board Member | 62 | 01-02-16 |
William Kaelin
BRD | Director/Board Member | 66 | 04-06-12 |
David Ricks
CEO | Chief Executive Officer | 56 | 01-01-96 |
Jamere Jackson
BRD | Director/Board Member | 54 | 01-10-16 |
Director/Board Member | 52 | 12-12-11 | |
Director/Board Member | 69 | 01-09-13 | |
Karen Walker
BRD | Director/Board Member | 62 | 01-12-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 950 566 452 | 947 814 267 ( 99,71 %) | 402 000 ( 0,0423 %) | 99,71 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
IMMUNOCORE HOLDINGS PLC 6.25% | 2 548 145 | 6.25% | 171 286 307 $ |
8 084 411 | 6.83% | 41 786 138 $ | |
4 000 000 | 9.47% | 30 920 000 $ | |
PROQR THERAPEUTICS N.V. 16.55% | 13 371 562 | 16.55% | 26 943 697 $ |
AC IMMUNE SA 3.66% | 3 615 328 | 3.66% | 13 087 487 $ |
PEIJIA MEDICAL LIMITED 2.94% | 19 952 740 | 2.94% | 12 947 133 $ |
21 776 804 | 7.60% | 11 627 289 $ | |
125 405 | 1.97% | 2 319 993 $ |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Eli Lilly SA
Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The private company is based in Vernier, Switzerland. |
Pharmaceuticals: Major
|
Kinsale Financial Services
| |
ELI Lilly & Company (India) Pvt Ltd.
ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India. |
Pharmaceuticals: Major
|
Lilly Ventures Fund I LLC
Lilly Ventures Fund I LLC Investment ManagersFinance Lilly Ventures Fund I LLC seeks investment opportunities located in the North American and European regions. The fund targets companies operating in the fields of biotechnology, medical technology and healthcare IT. It provides financing for early stage capital requirements. |
Investment Managers
|
Eli Lilly Export SA (Switzerland)
Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide. |
Medical Distributors
|
Eli Lilly Group Pension Trustees Ltd.
Eli Lilly Group Pension Trustees Ltd. Financial ConglomeratesFinance Part of Eli Lilly & Co., Eli Lilly Group Pension Trustees Ltd. operates as a British dormant company. The private company is based in Basingstroke, UK. |
Financial Conglomerates
|
Eli Lilly (Suisse) SA
| |
Eli Lilly Vostok SA
| |
Eli Lilly Services India Pvt Ltd.
Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The private company is based in Bangalore, India and was founded in 2015. |
Pharmaceuticals: Major
|
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+30,83% | 687 mld. | |
+30,96% | 595 mld. | |
+0,01% | 378 mld. | |
+15,18% | 316 mld. | |
+11,39% | 308 mld. | |
+0,78% | 211 mld. | |
-6,09% | 208 mld. | |
-2,92% | 203 mld. | |
-3,72% | 157 mld. | |
-5,94% | 145 mld. |
- Beurs
- Aandelen
- Aandeel Eli Lilly and Company - Nyse
- Onderneming Eli Lilly and Company